Meeting
2023 ASCO Annual Meeting
Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.
Authors
Mateus Trinconi Cunha
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, SP, Brazil
Mateus Trinconi Cunha , Felippe Lazar Neto , Maria Del Pilar Estevez-Diz , Renata Colombo Bonadio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5580)
DOI
10.1200/JCO.2023.41.16_suppl.5580
Abstract #
5580
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Real-world (RW) use of niraparib (Nir) monotherapy (mono) as first-line (1L) switch maintenance (1LSM) therapy following chemotherapy (CT) plus bevacizumab (bev) induction treatment in patients (pts) with epithelial ovarian cancer (EOC) in the SW1TCH study.
First Author: BJ Rimel
Poster
2023 ASCO Annual Meeting
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
First Author: Katherine Foster
Poster
2020 ASCO Virtual Scientific Program
NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.
First Author: Elena Ioana Braicu
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote